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Staphylococcus aureus (S. aureus) is an important opportunistic pathogen that may 
cause invasive life-threatening infections, like sepsis and pneumonia. Due to the increas-
ing antibiotic resistance, the development of an effective vaccine against S. aureus 
is needed. Although a correlate of protection against staphylococcal diseases is not 
yet established, several findings suggest that both antibodies and CD4 T cells might 
contribute to optimal immunity. In this study, we show that adjuvanting a multivalent 
vaccine (4C-Staph) with MF59, an oil-in-water emulsion licensed in human vaccines, 
further potentiated antigen-specific IgG titers and CD4 T-cell responses compared to 
alum and conferred protection in the peritonitis model of S. aureus infection. Moreover, 
we showed that MF59- and alum-adjuvanted 4C-Staph vaccines induced persistent 
antigen-specific humoral and T-cell responses, and protected mice from infection up to 
4 months after immunization. Furthermore, 4C-Staph formulated with MF59 was used 
to investigate which immune compartment is involved in vaccine-induced protection. 
Using CD4 T cell-depleted mice or B cell-deficient mice, we demonstrated that both T 
and B-cell responses contributed to 4C-Staph vaccine-mediated protective immunity. 
However, the role of CD4 T cells seemed more evident in the presence of low-antibody 
responses. This study provides preclinical data further supporting the use of the adju-
vanted 4C-Staph vaccines against S. aureus diseases, and provides critical insights on 
the correlates of protective immunity necessary to combat this pathogen.
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introduction
Staphylococcus aureus (S. aureus) is an important opportunistic 
pathogen that causes skin and soft tissue infections as well as 
invasive life-threatening diseases, including sepsis and pneu-
monia. It is estimated that this Gram-positive bacterium causes 
80,000 invasive infections each year in the US and about 15% of 
patients contracting invasive S. aureus succumb to this infection 
(1). Disease severity and increasing number of antibiotic-resistant 
strains urgently call for the development of an effective vaccine 
against this pathogen. So far, however, vaccines based on type 5 
and 8 capsular polysaccharides or on a single conserved protein 
antigen (IsdB) have failed in Phase III and II/III clinical trials, 
respectively (2, 3).
Although a correlate of protection has not yet been estab-
lished for staphylococcal infections, there are evidences that 
both humoral and cellular immunity are important to prevent 
staphylococcal diseases (4, 5). For example, immunocompromised 
individual with reduced ability to produce functional antibodies, 
such as acquired immune deficiency syndrome (6), or defects in 
immunoglobulin production (7), have increased susceptibility to 
staphylococcal infections. On the other hand, the help provided by 
CD4 T cells is required to develop functional antibody responses. 
Moreover, cytokines secreted by T helper cells like interferon-γ 
(IFN-γ) and IL-17 enhance recruitment and activation of neutro-
phils that are primary cellular defense against S. aureus infection 
and several groups have demonstrated that protection induced by 
vaccine candidates is mediated by these two cytokines in mouse 
animal models (1, 8, 9).
Based on the premises that humoral and cellular immune 
responses against multiple antigens might be needed to improve 
vaccine efficacy, we developed a protein-based vaccine (4C-Staph) 
targeting two surface-associated lipoproteins, FhuD2 and Csa1A, 
and three secreted virulence factors, α-Hemolysin (Hla), EsxA, 
and EsxB (10). FhuD2 is a lipoprotein involved in iron up-take 
and in early stages of invasive S. aureus infection (11–13). Csa1A 
is highly conserved across different S. aureus isolates and belongs 
to a family of proteins encoded in at least four distinct loci shar-
ing from 54 to 91% sequence identity (14). FhuD2 and Csa1A 
were shown to confer protection in the abscess animal model 
(12, 14). Hla plays a role in the early stages of invasive and skin 
infections (15), and was shown to confer protection in several 
mouse infection models of S. aureus, including pneumonia (16, 
17), peritonitis (10, 18), and dermonecrosis (15, 19). EsxA and 
EsxB are secreted through the ESAT-6 secretion system, which 
are involved in abscess formation (20–22). To be exploited as 
vaccine antigens, Hla was detoxified with a histidine to leucine 
substitution at position 35 (HlaH35L) (23), while EsxA and EsxB 
were fused together (EsxAB) (10). We previously demonstrated 
that 4C-Staph vaccine formulated with aluminum hydroxide 
(alum) was protective against several S. aureus strains in four 
animal models of infection: peritonitis, abscess formation, skin 
infection, and pneumonia (10, 24).
MF59 is an oil-in-water nano-emulsion licensed in 1997 to 
adjuvant human influenza vaccines and, to date, more than 150 
million doses of MF59-adjuvanted vaccines have been admin-
istered worldwide. Preclinical and clinical studies showed that 
MF59 adjuvant enhances both the quantity and the quality of 
antigen-specific immune responses, allowing for antigen dose-
sparing, improving the breadth of the antibody responses, and 
enhancing protective immunity in particular target populations, 
like children and the elderly (25).
Since the elderly is one of the populations most susceptible to 
S. aureus infection, we evaluated the adjuvant effect of MF59 on 
the immunogenicity and efficacy of 4C-staph vaccine in vivo and 
compared it to alum. Furthermore, we investigated the protec-
tive role of vaccine-specific antibody and CD4 T cells in B-cell 
deficient Jh mice or in mice depleted of CD4 T cells, respectively. 
Finally, the longevity of the protective immune responses induced 
by both vaccine formulations was evaluated by delaying the chal-
lenge up to 4 months after the last immunization.
Materials and Methods
growth of S. aureus Bacteria and Mouse 
challenge studies
For mouse in  vivo infection studies, S. aureus Newman strain 
(kindly provided by Professor Schneewind, University of Chicago) 
were grown in tryptic soy broth (Difco Laboratories) at 37°C with 
shaking until reaching mid-log phase. Bacteria were centrifuged, 
washed with PBS, and suspended in a volume of PBS to yield 
approximately 5  ×  109  colony-forming units (CFU)/ml. The 
inoculum was verified experimentally by plating on tryptic soy 
agar (Difco Laboratories) and colony enumeration the day after. 
Animals were challenged 2 weeks, 1 month or 4 months after the 
last immunization by intraperitoneal (i.p.) injection of S. aureus 
Newman (~5 × 108 CFU). Mice were monitored for survival daily 
for 1 or 2 weeks. Survival curves were generated using GraphPad 
Prism 6.04 software (GraphPad Software). Protective efficacy was 
calculated as [1 − (% dead4C-Staph/adjuvant/% deadadjuvant)] × 100.
animals and immunization Protocol
Female BALB/c or CD1 mice were purchased from Charles River 
Laboratories. Immunoglobulin (Ig) heavy chain-deleted Jh mice 
were purchased from Taconic. Five- to seven-week-old mice were 
used for all experiments. Mice were immunized intramuscularly 
(i.m.) with 10 μg of HlaH35L, FhuD2, EsxAB, and Csa1A (4C-Staph 
vaccine) in PBS, formulated 1:1 with MF59, or adsorbed to alu-
minum hydroxide adjuvant (alum, 2 mg/ml) in a total volume of 
100 μl (50 μl/quadriceps). Control mice received an equal volume 
of saline, MF59 or alum adjuvant, respectively. Mice received one 
or two injections 2 weeks apart.
luminex assay
Animals were bled immediately prior to the immunization, and 
2  weeks, 1  month, or 4  months after the last vaccination, and 
antigen-specific IgG present in sera of immunized mice were 
measured by Luminex technology (Luminex® 200 TM). HlaH35L, 
FhuD2, EsxAB, and Csa1A-purified proteins were covalently 
conjugated to the free carboxyl groups of microspheres using a 
Abbreviations: alum, aluminum hydroxide; CFU, colony-forming units; LOD, 
limit of detection; RLU, relative luminescence units; S. aureus, Staphylococcus 
aureus.
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N-hydroxysulfosuccinimide-enhanced carbodiimide-mediated 
conjugation chemistry. Antigen-specific antibodies were revealed 
using phycoerythrin-labeled secondary antibodies. Data are 
expressed as fluorescence intensity (relative luminescence unit, 
RLU/ml) at a fixed serum dilution.
hla neutralization assay
Inhibition of Hla-induced hemolysis by functional anti-4C-
Staph antibodies was evaluated in an in vitro assay as described 
elsewhere (10). Briefly, serial dilutions of sera from immunized 
mice were incubated with 12.5  nM Hla for 30  min at 37°C 
under constant agitation at 350 rpm. Erythrocytes derived from 
defibrinated rabbit blood were then added and the incubation 
prolonged for additional 30  min at 37°C. Incubation with 
water + 1% Triton X-100 was used as positive control (maximal 
hemolysis). Plates were then centrifuged for 5 min at 1,000 × g 
and the supernatant was analyzed by spectrophotometry at 
540 nm using a SpectraMax® 340PC384 Absorbance Microplate 
Reader (Molecular Devices).
elispot analysis of hlah35l-specific 
Plasmablasts
Splenocytes from immunized mice were collected 2 weeks after 
the second vaccination. Multiscreen HTS_HA plates (96-well, 
Millipore) were coated with 100 μl of PBS containing 10 μg/ml 
of HlaH35L or BSA, or 5 μg/ml of a goat anti-mouse Ig antibody 
(Southern Biotech), and blocked for 2 h at room temperature (RT) 
with PBS containing 10% fetal bovine serum. After three wash-
ing steps with PBS/Tween 20 0.05%, splenocytes (8 × 105 cells/
well) were seeded and incubated for 4 h at 37°C, 5% CO2. After 
six washing steps with PBS/Tween 20 0.05%, plates were incu-
bated overnight with biotin-conjugated goat anti-mouse Ig (BD 
Pharmigen), followed by 30  min incubation with horseradish 
peroxidase-conjugated streptavidin (Endogen), and developed 
with the AEC substrate kit (Sigma) following the manufacturer’s 
protocol. Spots of antibody-secreting cells were counted using 
a UV Spot ELISpot plate Analyzer (CTL) and the Immunospot 
software v5.1 Professional DC (CTL).
intracellular Flow cytometry
Splenocytes from immunized mice were isolated 2 weeks, 1 month 
or 4 months after the last immunization, plated at 1–2 × 106 cells/
well in 96-well plates, and stimulated with anti-CD28 and anti-
CD49d (2 μg/ml each, BD Biosciences), EsxAB, HlaH35L, FhuD2 or 
Csa1A (30 μg/ml), or with a combination of antigens (4C-Staph) 
containing EsxAB, HlaH35L, FhuD2, and Csa1A (10 μg/ml each) 
at 37°C for 16–18 h, in the presence of Brefeldin A (5 μg/ml) for 
the last 4 h. The cells were then stained with Live/Dead Yellow 
(Invitrogen), fixed, and permeabilized with Cytofix/Cytoperm 
(BD Biosciences), washed in Perm/Wash buffer (BD Biosciences), 
incubated with anti-CD16/CD32 Fc block (BD Biosciences) for 
20  min at RT, stained with fluorochrome-conjugated mAbs: 
anti-CD3-PerCP Cy5.5, anti-CD4-V500, anti-IFN-γ-PE, anti-IL-
2-APC, anti-TNF-Alexa700, anti-CD44-V450 (BD Pharmingen), 
anti-CD8-PE Texas Red (Invitrogen), anti-IL-17 PE-Cy7, anti-
IL-4-A488, and anti-IL-13-A488 (eBioscience), in Perm/Wash 
buffer 1× (BD Biosciences) for 20  min at RT, washed twice in 
Perm/Wash buffer, suspended in PBS. Samples were acquired on 
a LSRII special order flow cytometer (BD Biosciences) and T-cell 
responses were analyzed using FlowJo software (TreeStar) apply-
ing the gating strategy described in Figure S1 in Supplementary 
Material.
T-cell Proliferation
Splenocytes from immunized mice were collected at indicated 
time points, plated at 1 × 106/well in 96-well plates, stimulated 
with EsxAB, HlaH35L, FhuD2, and Csa1A (10 μg/ml each) at 37°C 
5% CO2 for 96 h and incubated for the last 24 h at 37°C 5% CO2 
in the presence of 10 μM of Click-it® Edu (Invitrogen). After two 
washing steps with PBS, cells were stained with Live/Dead Aqua 
(Invitrogen), incubated with anti-CD16/CD32 Fc block (BD 
Biosciences) for 20 min at RT in the dark and stained with anti-
CD4 Pacific Blue and anti-CD44 APC (BD Biosciences). Cells 
were fixed with Cytofix (BD Biosciences), Click-it® Edu detected 
following manufacturer’s instruction. Samples were acquired on 
a LSRII special order flow cytometer (BD Biosciences) and T-cell 
proliferation was analyzed using FlowJo software (TreeStar) apply-
ing the gating strategy described in Figure S1 in Supplementary 
Material.
Depletion of cD4 T cells
To deplete CD4 T cells, mice were injected i.p. with 100 μg of 
rat anti-mouse CD4 antibody, clone GK1.5 (Areta International), 
or with the same amount of rat IgG2b isotype control antibody 
(R&D system) according to the schematics shown in Figure S2A 
in Supplementary Material.
-  To abolish helper and effector CD4 T cells, animals received 
two injections of GK1.5 or isotype control antibodies before 
each immunization (on days 3 and 1, and on days 6 and 13, 
respectively).
-  To abolish effector CD4 T cells, animals received two injec-
tions of GK1.5 or isotype control antibodies 4 and 2  days 
before infection. Ten days after immunization, mice were 
challenged with S. aureus as described above.
CD4 depletion efficiency was evaluated by flow cytometry 
on heparinized blood after red blood cell lysis with RBC lysis 
buffer (Biolegend). Cells were stained with Live/Dead Yellow 
(Invitrogen), washed in PBS, incubated with anti-CD16/
CD32 Fc block (BD Biosciences) for 20  min at RT, stained 
with fluorochrome-conjugated mAbs: anti-CD3-PerCP Cy5.5 
(BD Pharmingen), anti-CD8-PE Texas Red (Invitrogen) and 
anti-CD4 Pacific Blue (Invitrogen), in PBS 0.1% BSA for 20 min 
at RT, washed twice in PBS 0.1% BSA, fixed with Cytofix (BD 
Biosciences), washed twice and suspended in PBS. No CD4 T cells 
were detected in the peripheral blood indicating that depletion 
occurred efficiently (Figure S2B in Supplementary Material) and 
maintained overtime (Figure S2C in Supplementary Material).
statistical analyses
Statistical analyses were performed using GraphPad Prism 6.04 
software (La Jolla, CA, USA). Experiments involving animal 
survival were analyzed by Mantle–Cox Log-rank test. Standard 
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one-way ANOVA followed by Tukey’s or Dunn’s multiple 
comparison tests were used for analyses involving more than 
two treatment groups, unless otherwise indicated. The p values 
<0.05 were considered significant. Data reported in this work are 
representative of at least two experiments.
ethics statement
All animal studies were carried out in compliance with current 
Italian legislation on the care and use of animals in experi-
mentation (Legislative Decree 116/92) and with the Novartis 
Animal Welfare Policy and Standards. Protocols were approved 
by the Italian Ministry of Health (authorization 249/2011-B). 
Following infection, mice were monitored daily and euthanized 
when they exhibited defined humane endpoints that were 
pre-established in agreement with Novartis Animal Welfare 
Policies.
results
4c-staph antigens Formulated with MF59 or 
alum confer Protection against S. aureus 
infection in the Peritonitis Mouse challenge 
Model
Efficacy of 4C-Staph vaccine was evaluated in the peritonitis 
model by immunizing mice once with 4C-Staph antigens 
alone, or in combination with MF59 or alum, or as control 
with saline or adjuvant alone. Two weeks after immunization, 
mice were infected i.p. with ~5 × 108 CFU S. aureus and then 
monitored for up to 2 weeks. 4C-Staph/MF59- and 4C-Staph/
alum-immunized mice showed significantly improved survival 
rates 7 days post-challenge compared to MF59 and alum adju-
vant control, respectively (Figure  1 left panel). The increased 
survival induced by 4C-Staph/MF59 and 4C-Staph/alum was 
similar, while 4C-Staph alone showed lower efficacy with no 
statistical difference compared to control mice immunized with 
saline. As expected, neither MF59 nor alum adjuvant alone 
conferred protection against S. aureus challenge. Similarly, an 
increased survival was measured after two immunizations with 
4C-Staph/MF59 and 4C-Staph/alum, while mice immunized 
with 4C-Staph alone did not show statistically significant dif-
ferences with control mice immunized with saline (Figure  1 
right panel). In the second week of observation, the survival 
decreased from 56 to 50% for 4C-Staph/MF59, from 46 to 40% 
for 4C-Staph/alum, and from 21 to 15% for 4C-Staph in the 
two immunizations regime (data not shown). In the single 
immunization regime, the survival decreased from 62 to 56% 
for 4C-Staph/MF59, from 56 to 53% for 4C-Staph/alum, and 
remained at about 10% for 4C-Staph. The protection for both 
adjuvanted vaccine formulations and schedules of immuniza-
tion remained statistically significant compared to controls 
receiving adjuvant alone. These data suggest that one immu-
nization is sufficient to induce a protective immune response 
against S. aureus infection, but only when the 4C-Staph anti-
gens are adjuvanted with MF59 or alum. Since a longer time 
of observation did not add value to the results, survival data 
will be reported at 1 week post-infection for all the subsequent 
challenge experiments.
characterization of humoral responses induced 
by adjuvanted 4c-staph antigens
Even though correlates of protection against S. aureus infection 
are yet to be established, there are evidences that antibodies are 
essential but not sufficient to prevent staphylococcal diseases. 
Passive transfer of hyper-immune sera directed against S. aureus 
antigens conferred protection in  vivo in animal models, and 
in vitro, antibodies inhibited the function of virulence factors and 
toxins, for example, Hla (10).
To characterize the immunogenicity of 4C-Staph formulations 
in term of antibody responses in mice, serum levels of IgG and 
IgM specific for each 4C-Staph antigen were measured after one 
or two vaccine administrations of 4C-Staph, 4C-Staph/MF59, and 
4C-Staph/alum. HlaH35L-specific IgG titers were readily detectable 
after one immunization in all groups of vaccinated mice, and IgG 
titers in the 4C-Staph/MF59 group reached a significant differ-
ence versus control mice that received MF59 alone (Figure 2A). 
In contrast, low (EsxAB) to undetectable (FhuD2 and Csa1A) 
levels of antigen-specific IgG were observed in all 4C-Staph-
vaccinated groups after a single immunization. The second dose 
boosted HlaH35L and EsxAB-specific antibody titers in all groups, 
however, the difference in IgG titers after one and two immuniza-
tions reached statistical significance only for 4C-Staph/MF59 and 
4C-Staph/alum. IgG isotypes were investigated for HlaH35L 2 weeks 
after the second immunization. MF59- and alum-adjuvanted 
4C-Staph vaccines elicited predominantly IgG1 (81 and 74%, 
respectively), followed by IgG2b (17 and 23%, respectively), and 
IgG2a (2 and 3%, respectively) (data not shown).
HlaH35L-specific IgM were detected in all vaccine groups at 
similar levels after a single immunization, and were not boosted by 
FigUre 1 | 4c-staph formulations increased the survival of mice after 
S. aureus infection. BALB/c mice were immunized with 4C-Staph, 
4C-Staph/MF59, 4C-Staph/alum, and respective controls (PBS, MF59, and 
alum) once or twice 2 weeks apart, and challenged 2 weeks after the last 
immunization with ~5 × 108 CFU S. aureus. Animals were monitored for 
7 days post-infection for health status. Graphs represent the merge of at 
least two separate experiments (n = 32). Statistical analyses were performed 
using Mantel–Cox test; survival in the groups receiving the formulated 
4C-Staph vaccines were compared to their respective control. *p < 0.05.
FigUre 2 | 4c-staph formulations induced antigen-specific functional 
antibody and antibody-secreting B cells. (a) IgG titers specific to each 
4C-Staph component (HlaH35L, EsxAB, FhuD2, and Csa1A) were determined in 
sera of mice after one (Post-1) or two (Post-2) immunizations (n = 10–16). 
(B) Correlation between Hla-specific neutralization and antibody titers. 
(c) HlaH35L-specific antibody-secreting B cells were detected in spleen of mice 
2 weeks after the second immunization (n = 4–8). Graphs show mean ± SD, 
and represent the merge of a least two separate experiments. Data were 
analyzed using one-way ANOVA and Tukey’s multiple comparison test, 
p < 0.05, *4C-Staph formulation versus its respective formulation without 
4C-Staph; #adjuvanted-4C-Staph versus 4C-Staph alone; $4C-Staph/MF59 
versus 4C-Staph/alum.
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the second injection of 4C-Staph vaccine formulations (Figure S3 
in Supplementary Material). In contrast, IgM responses against 
EsxAB, and IgM and IgG responses against FhuD2 and Csa1A 
were barely detectable, even after two immunizations.
Furthermore, the functional activity of Hla-specific antibod-
ies induced by the different 4C-Staph vaccine formulations was 
tested in an in  vitro neutralization assay and reported to the 
respective Hla-specific IgG titers. After two vaccine administra-
tions, sera from all 4C-Staph-immunized mice showed detect-
able Hla-neutralizing titers (Figure  2B). Titers were similar in 
MF59- and alum-adjuvanted 4C-Staph formulations, and were 
slightly lower in the non-adjuvanted 4C-Staph group. Sera from 
mice vaccinated once had no detectable Hla-specific neutralizing 
activity (data not shown).
To correlate IgG and neutralization titers with B-cell frequen-
cies, we evaluated the number of antigen-specific plasmablasts 
induced by the different 4C-Staph vaccine formulations. We 
observed that 4C-Staph/MF59 induced a higher frequency of 
HlaH35L-specific plasmablasts than 4C-Staph/alum and 4C-Staph 
alone (Figure 2C).
characterization of T-cell responses induced 
by adjuvanted 4c-staph antigens
As several groups have demonstrated that T cells may play a 
role in vaccine-mediated protection (1, 8, 9), we characterized 
the functional profile of 4C-Staph-specific T cells induced by the 
different vaccine formulations by polychromatic flow cytometry 
and intracellular cytokine staining (ICS) assay. T cells were gated 
as CD3+CD4+CD44hi cells after discrimination of singlets in live 
lymphocytes, defined morphologically by side scatter versus 
forward scatter plots (Figure S1A in Supplementary Material). 
The proliferation or production of IL-2, TNF, IFN-γ, IL-17, 
and IL-4/IL-13 was further determined on antigen-stimulated 
CD3+CD4+CD44hi T cells (Figure S1B in Supplementary Material).
4C-Staph-specific Edu+ proliferating CD4 T cells were 
observed after one immunization in 4C-Staph/MF59 and after two 
immunizations in 4C-Staph/MF59 and 4C-Staph/alum groups 
(Figure 3A). In addition, 4C-Staph-specific cytokine+ CD4 T cells 
were detected after one immunization in adjuvanted and non-
adjuvanted 4C-Staph-immunized mice, even though to a lesser 
extent in mice that received non-adjuvanted 4C-Staph antigens 
and were boosted by the second immunization (Figure 3B). The 
highest frequency of total cytokine+ CD4 T cells was observed 
in 4C-Staph/MF59-immunized mice, 2  weeks after the second 
immunizations, followed by 4C-Staph/alum and 4C-Staph. Most 
of the cytokine+ CD4 T cells were reactive to HlaH35L and EsxAB 
and to a lesser extent to FhuD2 and Csa1A (Figure 3C). When 
looking at the quality of the CD4 T-cell response, boolean gate 
analyses of the different cytokines (IL-2, TNF, IFN-γ, IL-17, and 
IL-4/IL-13) evidenced that, after one immunization, 4C-Staph/
MF59 induced the highest number of IFN-γ+ (Th1) and IL-17+ 
(Th17) CD4 T cells, with frequencies of 0.146 and 0.152% of 
total CD4+CD44high T cells, respectively, compared to 4C-Staph/
alum (0.103% for both IFN-γ and IL-17) and 4C-Staph (0.046 
and 0.049%, respectively) (Figure  3D). Frequencies of IL-2+, 
TNF+, and IL-2+TNF+ (Th0) CD4 T cells were also higher in 
FigUre 3 | 4c-staph formulations induced antigen-specific cD4 T 
cells. Splenocytes from individual mice were stimulated in vitro with 4C-Staph 
antigens and Edu, IFN-γ, IL-4, IL-13, IL-17, IL-2, and/or TNF positive 
CD4+CD44hi T cells were identified by flow cytometry using the gating strategy 
shown in Figure S1 in Supplementary Material. (a) Number of Edu+ proliferating 
CD4 T cells. (B,c) Frequency of cytokine+ CD4 T cells in response to 
stimulation with (B) all 4C-Staph antigens, or (c) with each single antigen 
(n = 10–18). (D) Pie charts representing polyfunctional CD4 CD44hi T cells. 
(e) Frequencies of CD4 T cells expressing one or more cytokines. Graphs 
represent the merge of two separate experiments, n = 10. Graphs show 
mean ± SD. Data were analyzed using one-way ANOVA and Tukey’s multiple 
comparison test, p < 0.05, *4C-Staph formulation versus its respective 
formulation without 4C-Staph; #adjuvanted-4C-Staph versus 4C-Staph alone; 
$4C-Staph/MF59 versus 4C-Staph/alum.
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the 4C-Staph/MF59 group compared to the other two groups, 
while 4C-Staph/alum induced the highest frequencies of IL-4/13+ 
(Th2) CD4 T cells, followed by 4C-Staph/MF59 and 4C-Staph. 
Two weeks after the second immunization, the magnitude of Th0, 
Th1, and Th2 CD4 T-cell responses increased in all three groups 
of vaccination, while Th17 decreased. 4C-Staph/MF59 induced 
the highest frequency of Th0, Th1, and Th17 combined (1.152%), 
followed by 4C-Staph (0.682%) and 4C-Staph/alum (0.339%). No 
significant differences in the proportion of CD4 T cells producing 
more than one cytokine were observed among 4C-Staph/MF59, 
4C-Staph/alum, and 4C-Staph (Figure 3E).
Altogether, these data show that 4C-Staph vaccine-induced 
antigen-specific IgM, IgG, and pluri-functional CD4 T cells, 
and adjuvanting 4C-Staph antigens with MF59 or alum showed 
increased antibody titers and frequencies of CD4 T cells com-
pared to non-adjuvanted antigens. 4C-Staph/MF59 vaccine 
formulation was selected to further characterize the immune 
mechanisms mediating protection against S. aureus infection.
contribution of 4c-staph-specific antibodies 
and cD4 T cells to the Protection against  
S. aureus
In order to determine the contribution of 4C-Staph-specific T 
cells and/or antibodies to the protection against S. aureus chal-
lenge, CD4 T cell-depleted BALB/c mice and Ig heavy chain 
deficient Jh mice were immunized once or twice with 4C-Staph/
FigUre 4 | B cells and cD4 T cells contribute to protection conferred 
by 4c-staph formulations. Mice were immunized once or twice with 
4C-Staph/MF59 or MF59 and challenged with S. aureus 10 days after the last 
immunization. Animals were monitored for 7 days post-infection for health 
status. (a,B) CD4 T cells were depleted in immunized BALB/c mice by i.p. 
injection of anti-CD4 or isotype control antibodies (n = 48) (a) 1–3 days before 
challenge, or (B) 1 day before each immunization. (c) Survival of B-cell 
knock-out Jh mice (n = 15). Graphs represent the merge of three separate 
experiments. Statistical analyses were performed using Mantel–Cox test, 
*p < 0.05.
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MF59 or with MF59 adjuvant alone as control. Two weeks after 
the last injection, mice were challenged with S. aureus Newman 
strain and their survival was monitored for 7 days.
CD4 T cells may have a dual role: as (i) effector cells through 
the release of cytokines and/or (ii) providers of cognate help to 
B cells for the production of antigen-specific functional IgG. To 
evaluate a possible role for any of these two CD4 T-cell popula-
tions in 4C-Staph/MF59-mediated protection against S. aureus, 
we depleted CD4 T cells by treating mice with anti-CD4 anti-
body or an IgG2b isotype control before or after immunization 
(Figure S2A in Supplementary Material). Mice immunized once 
with 4C-Staph/MF59 and depleted of CD4 T cells after vaccina-
tion shortly prior to S. aureus challenge showed a significantly 
decreased survival compared to isotype control-treated mice, 
while no differences in survival were seen between anti-CD4 and 
isotype treatments in mice immunized twice (Figure 4A). These 
data suggest that effector CD4 T cells may have a prominent role 
in protecting mice against rapid death by S. aureus in the presence 
of low 4C-Staph-specific IgM and IgG titers (single immuniza-
tion), while they might be dispensable at high antibody titers (two 
immunizations).
By depleting CD4 T cells before each of the two immuniza-
tions, 4C-Staph-specific CD4 T cells were not elicited, and IgG 
responses to all 4C-Staph antigens were decreased by up to 
two logs, while the frequency of CD4 T cells and magnitude of 
IgG responses in the isotype-treated group remained similar to 
that of untreated mice (Figures S2B and S4A in Supplementary 
Material). IgM titers were slightly reduced (HlaH35L and EsxAB) 
or not affected (FhuD2 and Csa1A) in CD4 T cell-depleted mice 
compared to isotype-treated and untreated groups (Figure S4B in 
Supplementary Material). In these conditions, CD4 T cell-depleted 
mice were significantly more susceptible to S. aureus infection 
than isotype control-treated mice (Figure  4B), suggesting that 
4C-Staph antigens are T cell-dependent antigens and that CD4 
T cells are required for the development of the humoral response 
that in turn contributes to the control of S. aureus infection.
Finally, antibody-deficient Jh mice immunized once or twice 
with 4C-Staph/MF59 were not protected against a lethal chal-
lenge with S. aureus, dying within 48 h of infection, and showed 
the same survival rate than mice treated with MF59 alone 
(Figure 4C).
Altogether, these data suggest that the presence of 4C-Staph-
specific antibody (IgG > IgM) is critical to the containment of S. 
aureus infection. Furthermore, in addition to their helper func-
tion, effector CD4 T cells may also participate to the mechanisms 
of protection when antibody titers are low.
4c-staph Vaccine induce Persisting immunity 
and long-lasting Protection
To evaluate the persistence of 4C-Staph-specific immunity, mice 
were vaccinated twice with 4C-Staph/MF59, 4C-Staph/alum, 
and the respective adjuvant alone as negative control. Sera and 
spleens were collected 1 month and 4 months after immunization 
to characterize 4C-Staph-specific antibody titers and CD4 T-cell 
responses, respectively.
4C-Staph-specific antibody titers were sustained in 4C-Staph-, 
4C-Staph/MF59-, and 4C-Staph/alum-immunized mice up to 
4 months after vaccination (Figure 5A). Titers remained higher 
in the two 4C-Staph-adjuvanted formulations at all time points 
evaluated. The magnitude of IgG responses of each vaccine 
formulation was antigen-dependent: alum formulation was 
more immunogenic than MF59 for Csa1A and FhuD2, MF59 
was more immunogenic for EsxAB, while alum- and MF59-
adjuvanted vaccines were equally immunogenic against Hla. 
Hla-neutralizing antibody titers were detected in all vaccinated 
groups 1  month after the second vaccine administration, and 
were sustained up to 4  months with no significant differences 
among non-adjuvanted and adjuvanted-4C-Staph formulations 
(Figure 5B).
One month after vaccination, frequencies of 4C-Staph-specific 
Edu+ and cytokine+ CD4 T cells were further increased in the 
4C-Staph/MF59 group. In contrast, the number of proliferating 
CD4 T cells were reduced in 4C-Staph and 4C-Staph/alum groups, 
while frequencies of cytokine+ CD4 T cells were maintained in 
the 4C-Staph group and were reduced in the 4C-Staph/alum 
group (Figures 5C,D). At 4 months, the magnitude of CD4 T-cell 
responses decreased in all groups receiving the 4C-Staph antigens, 
reaching frequencies similar or lower to those seen 2 weeks after 
FigUre 5 | Persistence of igg and cD4 T-cell responses induced by 
4c-staph formulations. BALB/c mice were immunized with 4C-Staph, 
4C-Staph/MF59 and 4C-Staph/alum (n = 10), and immune responses were 
determined 0.5, 1, and 4 months after immunization. (a) IgG titers specific to 
each 4C-Staph component (HlaH35L, EsxAB, FhuD2, and Csa1A) (n = 10–16). 
(B) Hla-specific neutralization titers. Number of (c) Edu+ proliferating and 
frequency of (D) cytokine+ CD4 T cells in response to in vitro stimulation with 
4C-Staph antigens. (e) Pie charts representing polyfunctional CD4 CD44hi T 
cells. (F) Frequencies of CD4 T cells expressing one or more cytokines. Graphs 
show mean ± SD, and are the merge of at least two separate experiments. 
Data were analyzed using one-way ANOVA and Tukey’s multiple comparison 
test, p < 0.05, *4C-Staph formulation versus its respective formulation without 
4C-Staph; #adjuvanted-4C-Staph versus 4C-Staph alone; $4C-Staph/MF59 
versus 4C-Staph/alum; †1 month or 4 months versus 0.5 month time point.
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FigUre 6 | 4c-staph formulations induced persistent protection 
against S. aureus. CD1 mice were immunized once or twice with 4C-Staph, 
4C-Staph/MF59, and 4C-Staph/alum (n = 10) and challenged with S. aureus 
0.5, 1, or 4 months after immunization. Animals were monitored for 7 days 
post-infection for health status. (a) Survival and (B) protective efficacy (PE) 
calculated (as described in Materials and Methods) on day 7 post-infection. 
Graphs represent the merge of at least two separate experiments (n = 16–24). 
Statistical analysis was performed using Mantel–Cox test; survival in the groups 
receiving the formulated 4C-Staph vaccines were compared to their respective 
control. *p < 0.05.
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two immunizations for 4C-Staph/MF59 and 4C-Staph/alum, 
respectively. Analysis of the cytokines secreted by 4C-Staph-
specific CD4 T cells mainly showed a contraction of IL-4+ CD4 
T cells between 1 and 4 months (Figure 5E). Furthermore, the 
frequencies of IL-17-producing T cells decreased 4 months after 
the second immunization (Figure 5E) compared to 2 weeks after 
the first injection (Figure 3D). Overall, the proportion of CD4 T 
cells producing 2 and 3 cytokines increased from 1 to 4 months 
(Figure 5F).
Finally, to evaluate whether the immune responses observed 
at later time point from vaccination were still protective, mice 
immunized once or twice with 4C-Staph/MF59 or 4C-Staph/
alum were challenged 1 month or 4 months after vaccination with 
S. aureus and their survival was monitored for 7 days. 4C-Staph/
MF59- and 4C-Staph/alum-immunized mice were still protected 
when challenged 1 or 4  months post-vaccination (Figure  6A). 
Protective efficacy (calculated as described in Materials and 
Methods) was higher at 1 month than 2 weeks after vaccination and 
sustained at least up to 4 months with both 4C-Staph/MF59 and 
4C-Staph/alum formulations (Figure 6B). Moreover, 4C-Staph/
MF59 outperformed 4C-Staph/alum at late time points. Similar 
results were observed if mice were infected after one or two vac-
cine injections. Altogether, these data suggest that 4C-Staph vac-
cine formulations induced levels of protective immune responses 
sustained at least for 4 months after immunization.
Discussion
Staphylococcus aureus is one of the most frequent causes of 
bacterial infection in humans. Despite the pressing medical need 
and the continued efforts, the development of a S. aureus vaccine 
remains a difficult goal not yet achieved. In the present study, 
we formulated 4C-Staph with MF59, an adjuvant licensed in 
human influenza vaccines targeting the elderly, a population also 
at higher risk of S. aureus infections. We demonstrated that both 
MF59- and alum-formulated 4C-Staph vaccines elicited persist-
ing protective immune responses, and increased the survival rates 
after a lethal challenge with S. aureus in a mouse peritonitis model 
of infection. 4C-Staph/MF59 induced high levels of antigen-
specific IgM, IgG, plasmablasts, CD4 T cells (Th0/Th1/Th17) and 
long-term protection. Dissecting the mechanism(s) of 4C-Staph/
MF59-mediated protection, using B-cell deficient and CD4 T 
cell-depleted mice, revealed that 4C-Staph-specific antibodies 
were critical to the containment of S. aureus infection, while the 
contribution of effector CD4 T cells was most pronounced at 
low antibody titers. Altogether, these data suggest that, in the S. 
aureus peritonitis model, a vaccine formulation inducing both 
antibodies and T cells might be preferred.
The inability of adjuvanted and non-adjuvanted 4C-Staph 
vaccine formulations to protect Jh mice from S. aureus lethal 
infection confirmed the importance of antibodies in protecting 
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against S. aureus infection as already reported in animal models 
(10, 12) and also supported by human studies (26–29). However, 
several vaccines against S. aureus infection that elicited high 
antibody titers (3, 30) failed in phase III clinical trials, despite 
encouraging preclinical results (3, 30–32). In addition, evidences 
supporting a role for T cell-mediated immunity in host defense 
against S. aureus infections are emerging in human studies and 
in animal models. For example, patients with poorly controlled 
HIV and low CD4 T-cell counts have high rates of S. aureus skin 
and soft tissue infections [reviewed in Ref. (33)]. Furthermore, 
patients with the Hyper-IgE syndrome, in which Th17 function is 
impaired, are highly susceptible to S. aureus skin and lung infec-
tions (34), as are mice that are deficient in IL-17 (35, 36). Th17 
cells have also proven to be relevant in the protection conferred 
by IsdB vaccine against lethal S. aureus i.v. infection (9). Recently, 
Montgomery et al. showed that both antibody and Th17 responses 
were conferring protective immunity in a mouse model of skin 
infection (37). Therefore, targeting T-cell responses against 
S. aureus, in addition to humoral responses, may be critical in 
developing protection against infection. In this study, we report 
that a single immunization of non-adjuvanted 4C-Staph antigens 
elicited CD4 T-cell responses whose magnitude increased in the 
presence of an adjuvant, and were further boosted by the second 
vaccine administration. By means of multiparameter flow cytom-
etry, we characterized the quality of the T-cell responses following 
immunization and showed that the highest number of antigen-
specific Th0, Th1, and Th17 cells was induced by 4C-Staph/MF59. 
In an effort to establish the contribution of antigen-specific CD4 
T cells to the protection conferred by 4C-Staph/MF59, CD4 T 
cells were depleted in immunized mice. CD4 T-cell depletion 
experiments demonstrated that CD4 T cells were crucial to 
the development of antigen-specific humoral responses and in 
turn to vaccine-induced protection. In addition to their helper 
function, effector CD4 T cells also contributed to protection 
against S. aureus, probably through the production of cytokines 
that enhanced the recruitment and activation of innate immune 
cells, such as neutrophils, key players in the control of S. aureus 
infection (38). The role of effector CD4 T cells was more evident 
when antibody titers were low (CD4 T-cell depletion after a single 
immunization), while their contribution to protection was not 
appreciable in presence of high antibody titers (CD4 T-cell deple-
tion after two immunizations). Notably, the frequency of IL-17-
producing CD4 T cells was the highest after one immunization. 
These observations may suggest a role for IL-17+ CD4 T cells in 
protection against S. aureus, in agreement with published data (9, 
34–36, 39, 40). Surprisingly, we showed that the percent survival 
was not different in mice that received one or two vaccine admin-
istrations, despite significantly different antibody titers. On the 
other hand, we detected a Th1/Th17 bias more pronounce after 
one immunization that could be in turn responsible for vaccine-
induced protection after a single vaccination. We can speculate 
that in conditions of sub-optimal humoral responses, the role of 
CD4 T cells, and in particular Th1/Th17 responses, become more 
evident in contributing to protection against bacterial infection. 
Along these lines, we recently reported that 4C-Staph formulated 
with alum and a TLR7 agonist small molecule immunopotentia-
tor (4C-Staph/T7-alum) shifted CD4 T cell polarization toward 
Th1/Th17 and significantly increased protection against S. aureus 
infection compared to 4C-Staph/alum (10). While T7-alum 
adjuvant might hold great promise in the future, it is not readily 
available as safety in humans has yet to be confirmed.
Taken together, the results presented in this study dem-
onstrated that rationally designed first generation 4C-Staph 
vaccine, formulated with alum or MF59, two adjuvants licensed 
in human vaccines, induced persistent protection, albeit partial, 
in an animal model of S. aureus-induced peritonitis, and that 
4C-Staph-specific antibodies and CD4 T cells contributed to the 
protective mechanisms.
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